# A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma

> **NCT06472895** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** AK112 monotherapy

## Key facts

- **NCT ID:** NCT06472895
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-20
- **Primary completion:** 2025-12-20
- **Final completion:** 2027-12-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06472895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06472895, "A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06472895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*